The initial CD4 CAR treatment preclinical trial, assessing its safety and efficacy, was undertaken by Huda Salman et al. The result showed that it was effective at killing CD4 + AML cells in culture and in animals [112]. The gene discussed is CD4; the disease is acute myeloid leukemia.